Camp4 Therapeutics Corp
CAMP Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$3.21
KIRA · Stoqly’s AI analyst, in plain words
- Camp4 Therapeutics Corp had $3.5M of revenue in fiscal 2025, up 436.5% on the year before.
- Its operating margin was −1,502.4%, up 6,639.9 pts: of every 100 in sales, about −1,502 is left after running the business.
- Camp4 Therapeutics Corp lost $80.4M in fiscal 2025.
- Free cash flow was −$29.8M in fiscal 2025, −852.8% of revenue.
Market cap
$186M
P/E
—
Revenue
$3.5M
Net income
−$80.4M
Free cash flow
−$29.8M
Operating margin
−1,502.4%
Camp4 Therapeutics Corp in 30 seconds · fiscal 2025
Are sales growing?
+436.5%
Yes. Sales grew 436.5% last year.
Does it make a profit?
−2,298.5%
No. It lost money last year.
Does profit turn into cash?
−852.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Camp4 Therapeutics Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Camp4 Therapeutics Corp
- CIK
- 0001736730
Camp4 Therapeutics Corp · CAMP
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $0.4M | $0.7M | $3.5M |
| Revenue growth | — | 86.3% | 436.5% |
| Operating margin | −14,822.6% | −8,142.3% | −1,502.4% |
| Net income | −$49.3M | −$51.8M | −$80.4M |
| Net margin | −14,083.1% | −7,943.4% | −2,298.5% |
| Diluted EPS | −$124.80 | −$11.04 | −$2.65 |
| Cash | |||
| Cash from operations | −$44.2M | −$45.6M | −$29.6M |
| Capital expenditure | $0.7M | $0.4M | $0.3M |
| Free cash flow | −$44.8M | −$46.0M | −$29.8M |
| FCF margin | −12,809.4% | −7,055.7% | −852.8% |
| Share count change | — | 1,087.4% | 547.8% |
| Debt and strength | |||
| Cash and short-term investments | $38.4M | $64.0M | $110M |
| Shareholders' equity | −$124M | $63.1M | $47.7M |
| Current ratio | 5.1x | 6.9x | 7.4x |
| Returns and quality | |||
| Return on equity | — | — | −145.1% |
| Return on tangible equity | — | −82.0% | −168.5% |
| Piotroski F-score | — | 4 | 3 |
| Altman Z'' | −19.9 | −4.2 | −4.9 |
Insiders bought, 12 months
$0.1M
4 insiders
Insiders sold, 12 months
$2.5M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Camp4 Therapeutics Corp · CAMP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.21 a share, the company is worth $186M.
Source: SEC EDGAR XBRL filings (CIK 0001736730). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.